A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies
Open Access
- 11 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 12 (6), 1-11
- https://doi.org/10.1038/s41419-021-03889-0
Abstract
Acute promyelocytic leukemia (APL) is characterized by a specific chromosome translocation involving RARα and its fusion partners. For decades, the advent of all-trans retinoic acid (ATRA) synergized with arsenic trioxide (As2O3) has turned most APL from highly fatal to highly curable. TBLR1-RARα (TR) is the tenth fusion gene of APL identified in our previous study, with its oncogenic role in the pathogenesis of APL not wholly unraveled. In this study, we found the expression of TR in mouse hematopoietic progenitors induces blockade of differentiation with enhanced proliferative capacity in vitro. A novel murine transplantable leukemia model was then established by expressing TR fusion gene in lineage-negative bone marrow mononuclear cells. Characteristics of primary TR mice revealed a rapid onset of aggressive leukemia with bleeding diathesis, which recapitulates human APL more accurately than other models. Despite the in vitro sensitivity to ATRA-induced cell differentiation, neither ATRA monotherapy nor combination with As2O3 confers survival benefit to TR mice, consistent with poor clinical outcome of APL patients with TR fusion gene. Based on histone deacetylation phenotypes implied by bioinformatic analysis, HDAC inhibitors demonstrated significant survival superiority in the survival of TR mice, yielding insights into clinical efficacy against rare types of APL.Keywords
Funding Information
- National Natural Science Foundation of China (81770181)
This publication has 45 references indexed in Scilit:
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progressionJCI Insight, 2011
- PML–RARα initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitorsLeukemia, 2009
- Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARαOncogene, 2004
- PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitorsBlood, 2002
- The Signal Transducer and Activator of Transcription STAT5b Gene Is a New Partner of Retinoic Acid Receptor in Acute Promyelocytic-Like LeukaemiaHuman Molecular Genetics, 1999
- Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patientOncogene, 1999
- Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APLNature Genetics, 1998
- Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemiaNature Genetics, 1997
- Treatment of Acute Promyelocytic Leukemia: A Report of 70 CasesLeukemia & Lymphoma, 1991